Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC
NCT07819578Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and sacituzumab tirumotecan in non-small cell lung cancer (NSCLC). Primary endpoint: Pathological Complete Response Rate up to 18 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
toripalimabsacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07819578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819578.